RenalGuard Solutions has announced the treatment of 20,000 patients with RenalGuard for the prevention of contrast-induced nephropathy. A press release reports that the system, which is currently used in Europe and other countries that recognise the CE mark, is designed to reduce the incidence of contrast-induced nephropathy found in the millions of at-risk patients undergoing cardiovascular imaging procedures by managing real-time fluid balance in conjunction with interventional procedures involving contrast media.
The press release adds that a number of studies have demonstrated RenalGuard’s ability to protect patients from AKI following catheterization procedures when compared to the standard of care.
Bjoern Andrew Remppis (Herz- und Gefässzentrum, Bad Bevensen, Germany) says: “Our hospital has treated over 700 patients with RenalGuard Therapy, and has established a pathway to ensure patients with chronic kidney disease are identified and receive appropriate treatment. In many cases, patients display a broad range of diuretic efficiency and fluid balance within hours. Our institution is happy to have an option for patients that circumvents contrast media, which are associated with worsening kidney function. We will continue to look to RenalGuard as an important therapy in the field of cardio-renal medicine and are intrigued at the potential of this valuable tool for automated negative volume management in heart failure patients.”
Jim Dillon, CEO, RenalGuard Solutions notes: “We are very pleased by the positive response in the medical community in Europe towards the use of RenalGuard in high-risk patients undergoing cardiovascular procedures,” said “This is a huge milestone for the product, the company, and our patients.”
RenalGuard Solutions will demonstrate RenalGuard Therapy at the 2018 annual meeting of the European Society of Cardiology (ESC; 25–29 August, Munich, Germany; Booth G400) and at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) meeting (21–25 September, San Diego, USA; Booth 823).
